Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research shows antibody offers new target for anti-inflammatories
The researchers from the Burnham Institute for Medical Research found that a naturally “tweaked” sugar chain, normally present on white blood cells and intestinal cells, plays a role
The researchers from the Burnham Institute for Medical Research found that a naturally “tweaked” sugar chain, normally present on white blood cells and intestinal cells, plays a role
The FDA approved the storage labeling change based on data from testing to assure the labeled potency remains within specified limits through the expiration date of the product.
The placebo-controlled trial will evaluate the ability of rifalazil to improve symptoms of peripheral arterial disease (PAD) by assessing improvements in peak walking time. PAD is a serious
The study is designed to evaluate the safety and preliminary efficacy of PV-10 in five subjects with recurrent breast carcinoma. PV-10 will be injected into one or more
The approval was based on the intergroup exemestane study (IES) which showed that patients who switched to Aromasin after 2-3 years of tamoxifen, for a combined total of
Under the terms of the contract, DVC will develop and optimize preclinical testing models, assess immune response and develop new tularemia vaccine candidates. The company will collaborate on
The new indication includes the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to other systemic therapy. The European Commission approval results
The data show that TroVax is safe and well-tolerated in the renal cell carcinoma patient group and that it induces a strong anti-tumour immune response against the 5T4
Using its antibody technology, Abmaxis will further optimize and humanize antibodies developed by BioArctic. Under the terms of the agreement, BioArctic will pay Abmaxis an upfront technology license
Although the secretin drug, RG1068, proved ineffective in treating positive symptoms of the disease during a previous phase II trial, several patients showed cognitive improvements following drug administration.